Adjuvant chemotherapy for completely resected non-small cell lung cancer: A systematic review

被引:22
作者
Alam, Naveed
Darling, Gail
Evans, William K.
Mackay, Jean A.
Shepherd, Frances A. [1 ]
机构
[1] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Hamilton Hlth Sci, Juravinski Canc Ctr, Hamilton, ON, Canada
[5] McMaster Univ, Canc Care Ontario Program Evidence Based Care, Downtown Ctr, Hamilton, ON L8S 4L8, Canada
关键词
adjuvant treatment; chemotherapy; non-small cell lung cancer;
D O I
10.1016/j.critrevonc.2005.10.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To conduct a systematic review and to evaluate the impact of postoperative adjuvant chemotherapy on the survival of patients with completely resected non-small cell lung cancer. Methods: Relevant randomized trials and meta-analyses, published as articles or abstracts, were identified through electronic and hand searches by two reviewers. Results: Seven meta-analyses and 26 randomized trials comparing surgery with or without chemotherapy met the pre-defined eligibility criteria for the review. The meta-analyses all showed a survival advantage for platinum- or UFT-based postoperative chemotherapy, although the results did not always achieve statistical significance. The results of individual trials were inconsistent, although recent trials have detected a large survival advantage with postoperative platinum-based chemotherapy. Differences in trial design, patient characteristics, disease stage, use of radiotherapy and chemotherapy regimen may explain the variation in results. Conclusions: Postoperative adjuvant platinum-based chemotherapy improves survival compared with surgery alone in completely resected non-small cell lung cancer. In patients fit for chemotherapy, the survival benefits strongly outweigh the adverse effects of the treatment. (c) 2005 Cancer Care Ontario. Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:146 / 155
页数:10
相关论文
共 51 条
[11]  
Dautzenberg B, 1999, CANCER-AM CANCER SOC, V86, P265, DOI 10.1002/(SICI)1097-0142(19990715)86:2<265::AID-CNCR10>3.0.CO
[12]  
2-B
[13]  
DOUILLARD JY, 2005, ASCO ORG VIRT M
[14]  
DOUILLARD JY, 2005, J CLIN ONCOL, V23, pA7013
[15]   A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery [J].
Endo, C ;
Saito, Y ;
Iwanami, H ;
Tsushima, T ;
Imai, T ;
Kawamura, M ;
Kondo, T ;
Koike, K ;
Handa, M ;
Kanno, R ;
Fujimura, S .
LUNG CANCER, 2003, 40 (02) :181-186
[16]   ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN IN PATIENTS WITH COMPLETELY RESECTED STAGE-I NON-SMALL-CELL LUNG-CANCER [J].
FELD, R ;
RUBINSTEIN, L ;
THOMAS, PA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (04) :299-306
[17]  
George, 1998, Oncologist, V3, P35
[18]   Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer [J].
Hamada, C ;
Tanaka, F ;
Ohta, M ;
Fujimura, S ;
Kodama, K ;
Imaizumi, M ;
Wada, H .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4999-5006
[19]   SURGICAL ADJUVANT THERAPY FOR STAGE-II AND STAGE-III ADENOCARCINOMA AND LARGE-CELL UNDIFFERENTIATED CARCINOMA [J].
HOLMES, EC ;
GAIL, M .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (05) :710-715
[20]   Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: Reappraisal with a meta-analysis of randomized controlled trials [J].
Hotta, K ;
Matsuo, K ;
Ueoka, H ;
Kiura, K ;
Tabata, M ;
Tanimoto, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (19) :3860-3867